Merck Issues Update on Phase III Trial for Preladenant

Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2[A ]receptor antagonist for the treatment of Parkinson's disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy